Related Experiment Video
Updated: Jul 16, 2025

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in
Simon Lebek1,2,3, Xurde M Caravia1,2, Francesco Chemello1,2
1Department of Molecular Biology (S.L., X.M.C., F.C., W.T., J.R.M., N.L., R.B.-D., E.N.O.), University of Texas Southwestern Medical Center, Dallas.
Insights
Gene editing to block CaMKIIδ overactivation significantly improved cardiac function and survival in a mouse model of heart failure. This approach shows promise for treating human cardiac diseases by targeting a key enzyme in cardiac dysfunction.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Gene Editing Technologies
Background:
- Cardiovascular diseases are a leading cause of death globally, necessitating novel therapeutic strategies.
- Overactivation of the cardiac enzyme Ca2+/calmodulin-dependent protein kinase IIδ (CaMKIIδ) is a key factor in various heart disorders.
Purpose of the Study:
- To develop a gene-editing therapy for heart failure by targeting the autophosphorylation site of CaMKIIδ.
- To assess the efficacy and safety of CRISPR-Cas9 adenine base editing in a mouse model of heart failure and in human cells.
Main Methods:
- CRISPR-Cas9 adenine base editing was used to create a phospho-resistant CaMKIIδ mutation in mice.
- Mice underwent transverse aortic constriction to induce heart failure; cardiac function, gene expression, apoptosis, and fibrosis were evaluated.
- Human induced pluripotent stem cells were edited to target the homologous CaMKIIδ site, with specificity assessed via deep amplicon sequencing.
Main Results:
- Gene-edited mice exhibited significantly reduced mortality (11% vs. 65%) and improved cardiac function post-heart failure induction compared to wild-type mice.
- CaMKIIδ-edited mice were protected against heart failure-induced changes in gene expression, apoptosis, and fibrosis.
- Edited human cells and cardiomyocytes showed protection against Ca2+ dysregulation and arrhythmias under stress, with high editing specificity for CaMKIIδ.
Conclusions:
- Ablating CaMKIIδ autophosphorylation via adenine base editing offers a potential therapeutic strategy for human cardiac diseases.
- The high specificity of the gene editing tool for CaMKIIδ is a critical safety feature for potential clinical translation.
Background:
Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders.
Methods:
To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ. We generated mice harboring a phospho-resistant CaMKIIδ mutation in the germline and subjected these mice to severe transverse aortic constriction, a model for heart failure. Cardiac function, transcriptional changes, apoptosis, and fibrosis were assessed by echocardiography, RNA sequencing, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and standard histology, respectively. Specificity toward CaMKIIδ gene editing was assessed using deep amplicon sequencing. Cellular Ca2+ homeostasis was analyzed using epifluorescence microscopy in Fura-2-loaded cardiomyocytes.
Results:
Within 2 weeks after severe transverse aortic constriction surgery, 65% of all wild-type mice died, and the surviving mice showed dramatically impaired cardiac function. In contrast to wild-type mice, CaMKIIδ phospho-resistant gene-edited mice showed a mortality rate of only 11% and exhibited substantially improved cardiac function after severe transverse aortic constriction. Moreover, CaMKIIδ phospho-resistant mice were protected from heart failure-related aberrant changes in cardiac gene expression, myocardial apoptosis, and subsequent fibrosis, which were observed in wild-type mice after severe transverse aortic constriction. On the basis of identical mouse and human genome sequences encoding the autophosphorylation site of CaMKIIδ, we deployed the same editing strategy to modify this pathogenic site in human induced pluripotent stem cells. It is notable that we detected a >2000-fold increased specificity for editing of CaMKIIδ compared with other CaMKII isoforms, which is an important safety feature. While wild-type cardiomyocytes showed impaired Ca2+ transients and an increased frequency of arrhythmias after chronic β-adrenergic stress, CaMKIIδ-edited cardiomyocytes were protected from these adverse responses.
Conclusions:
Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.
Related Concept Videos
CRISPR
CRISPR/Cas9 Genome Editing

